⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
166,064.81
+0.06%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.05
+0.19%
Gold
$4,132.45
−0.20%
Brent
$109.90
+0.62%
BTC
$81,868.52
+0.03%
ETH
$2,402.55
−0.11%
DFM General
5,851.39
−0.27%
FTSE ADX
9,783.24
−0.26%
TASI
10,123.62
−0.65%
QE Index
8,632.66
−0.01%
S&P 500
7,690.73
+0.41%
Nasdaq 100
29,529.34
+1.17%
Nifty 50
22,888.95
−1.11%
Sensex
73,852.90
−1.17%
KSE-100
166,064.81
+0.06%
DFM:EMIRATESNBD
AED 31.50
−0.25%
ADX:IHC
AED 352.00
−0.17%
SAU:2222
SAR 25.80
+0.00%
DSMD:QNBK
QAR 15.66
+2.29%
NAS:NVDA
$217.09
+1.38%
NYSE:TSM
$420.22
+1.84%
NSE:RELIANCE
₹1,202.00
−0.76%
KAR:OGDC
Rs 300.05
+0.19%
Gold
$4,132.45
−0.20%
Brent
$109.90
+0.62%
BTC
$81,868.52
+0.03%
ETH
$2,402.55
−0.11%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Closed
🇵🇰
Pakistan
PSX · KSE-100
Open
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› REGN
R
Regeneron Pharmaceuticals Inc
NAS:REGN
Healthcare
CBOE:SPESG
NASDAQ:NBI
$782.04
−1.10%
At close
At close · Tue 20 Oct · ≈
AED 2,872.04
· Market cap
$80.51B
· Next earnings
Wed 28 Oct
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Regeneron Pharmaceuticals Inc · News · TradingHolo
REGN news
Headlines tagged to this company
RE
Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement
Reuters · 14 d ago
TR
Regeneron Expands Sanofi Antibody Pact; $1 Billion Upfront, Up to $7 Billion in Milestones
TradingView · 14 d ago
GL
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
GlobeNewswire · 14 d ago
SE
Notable healthcare headlines for the week: Pfizer, Sanofi, and Novartis in focus
Seeking Alpha · 16 d ago
RE
Major drugmakers turn to China for licensing deals
Reuters · 18 d ago
DO
Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals — Market Talk
Dow Jones Newswires · 18 d ago
DO
Regeneron Pharma Price Target Raised to $930.00/Share From $870.00 by Jefferies
Dow Jones Newswires · 18 d ago
ST
Why Regeneron (REGN) Stock Is Trading Lower Today
Stock Story · 19 d ago
SE
Regeneron drops after early-stage trial data for ovarian cancer therapy
Seeking Alpha · 19 d ago
DO
Regeneron's Trevogrumab Prevented Muscle Loss in GLP-1 Users During Trial
Dow Jones Newswires · 19 d ago
RE
Regeneron Phase 2 Trial Shows Trevogrumab Prevents Muscle Loss During GLP-1 Weight Loss
Reuters · 19 d ago
RE
Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients
Reuters · 19 d ago
GL
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
GlobeNewswire · 19 d ago
TR
Regeneron Pharmaceuticals, Inc. (REGN) Phase 2 Shows Trevogrumab Preserved Muscle in GLP-1 Weight Loss
TradingView · 19 d ago
QU
REGN: Expanded alliance targets next-gen Type 2 therapies with equal cost and profit sharing
Quartr · 19 d ago
DO
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
Dow Jones Newswires · 19 d ago
QU
REGN: Expanded alliance targets next-gen type 2 medicines with equal cost/profit sharing and $8B in payments
Quartr · 19 d ago
DO
Regeneron Pharma Price Target Announced at $850.00/Share by Argus Research
Dow Jones Newswires · 19 d ago
ST
Regeneron, Sanofi Expand Immunology Alliance With $1B Upfront Payment: Here Are The Key Highlights
Stocktwits · 19 d ago
← Previous
More news →